Cargando…

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species

CD101 is a novel semisynthetic echinocandin with antifungal activity against Candida and Aspergillus spp. The pharmacokinetics (PK) of CD101 administered intravenously to mice, rats, dogs, cynomolgus monkeys, and chimpanzees are presented. CD101 consistently exhibited very low clearance, a modest vo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ong, Voon, James, Kenneth D., Smith, Steven, Krishnan, B. Radha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365648/ https://www.ncbi.nlm.nih.gov/pubmed/28137817 http://dx.doi.org/10.1128/AAC.01626-16

Ejemplares similares

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
por: Ong, Voon, et al.
Publicado: (2016)

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
por: James, Kenneth D., et al.
Publicado: (2017)

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
por: Sandison, Taylor, et al.
Publicado: (2017)

CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms
por: Chandra, Jyotsna, et al.
Publicado: (2018)

CD101: a novel long‐acting echinocandin
por: Zhao, Yanan, et al.
Publicado: (2016)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
por: Zhao, Yanan, et al.
Publicado: (2018)

Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
por: Locke, Jeffrey B., et al.
Publicado: (2016)

Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model
por: Zhao, Yanan, et al.
Publicado: (2017)

Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants
por: Cheung, Yuk-Yam, et al.
Publicado: (2017)

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial
por: Thakkar, Nilay, et al.
Publicado: (2018)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206
por: Bruss, Jon, et al.
Publicado: (2021)

Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101
por: Ohana, G, et al.
Publicado: (2003)

Echinocandins Accelerate Particle Transport Velocity in the Murine Tracheal Epithelium: Dependency on Intracellular Ca(2+) Stores
por: Müller, Sabrina, et al.
Publicado: (2021)

In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis
por: Boikov, Dina A., et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
por: Zhang, Cindy X., et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B
por: Guptill, J. T., et al.
Publicado: (2021)

Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents
por: Ireson, C R, et al.
Publicado: (2004)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1
por: Park, A. Young J., et al.
Publicado: (2022)

Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
por: Lomeli, Barbara K., et al.
Publicado: (2019)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
por: Lepak, Alexander J, et al.
Publicado: (2017)

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
por: Pfaller, Michael A., et al.
Publicado: (2016)

Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis
por: Hager, Christopher, et al.
Publicado: (2017)

Photodynamic therapy effect of m-THPC (Foscan®) in vivo: correlation with pharmacokinetics
por: Jones, H J, et al.
Publicado: (2003)

Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
por: Duthaler, Urs, et al.
Publicado: (2016)

Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
por: Lakshminarayana, Suresh B., et al.
Publicado: (2015)

Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats
por: Verschraagen, M, et al.
Publicado: (2004)

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)

Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
por: Dawson, Rodney, et al.
Publicado: (2023)

Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats
por: Ireson, C R, et al.
Publicado: (2004)

In Silico-Based High-Throughput Screen for Discovery of Novel Combinations for Tuberculosis Treatment
por: Singh, Ragini, et al.
Publicado: (2015)

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
por: Ji, Xi-wei, et al.
Publicado: (2020)

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
por: Francis, Jose, et al.
Publicado: (2019)

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
por: Zhao, Yanan, et al.
Publicado: (2020)

Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia
por: Frydecka, I, et al.
Publicado: (2004)

Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene
por: Sale, S, et al.
Publicado: (2004)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_avo4erpgv1ftrg0rov4qjuh9hc